News | June 03, 2026
Eurofragance and MartiDerm launch free skincare line to tackle 'fish odor syndrome'
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The approval is supported by results from the Phase 3 SWOG 1826 trial
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
